Trans-tace: Prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma

62Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

The aim of the present study was to correlate laboratory data and postprocedural parameters after conventional transarterial chemoembolization (cTACE) for hepatocellular carcinoma (HCC) with the radiological response. The study consisted of a retrospective analysis of prospectively collected data from 70 consecutive patients who underwent cTACE. Laboratory parameters were assessed daily after cTACE and compared to pretreatment values. Post-treatment radiological response was assessed using mRECIST at one month from cTACE, and factors associated with treatment response (complete and objective response) were assessed by logistic regression analysis. The optimal cutoff points in predicting the complete response of target lesions were a 52% ALT and a 46% AST increase after cTACE compared to the pre-treatment values. Using multivariate analyses, >46% AST and >52% ALT increases with respect to the pre-treatment value were significantly correlated with the objective response (p = 0.03 and p = 0.04, respectively) and the complete response (p = 0.02 and p = 0.02, respectively). No patients experienced liver function deterioration after cTACE, and no specific treatment was required. This study showed that post-treatment transient transaminase elevation was predictive of objective response to superselective cTACE in clinical practice, representing a simple tool to guide treatment strategy of HCC patients in a tailored approach.

References Powered by Scopus

Global cancer statistics, 2002

17722Citations
N/AReaders
Get full text

Transection of the oesophagus for bleeding oesophageal varices

7322Citations
N/AReaders
Get full text

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

6697Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center

43Citations
N/AReaders
Get full text

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

35Citations
N/AReaders
Get full text

Initiative on Superselective Conventional Transarterial Chemoembolization Results (INSPIRE)

26Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Granito, A., Facciorusso, A., Sacco, R., Bartalena, L., Mosconi, C., Cea, U. V., … Renzulli, M. (2021). Trans-tace: Prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. Journal of Personalized Medicine, 11(10). https://doi.org/10.3390/jpm11101041

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Nursing and Health Professions 1

100%

Save time finding and organizing research with Mendeley

Sign up for free